NasdaqGS:ABCLLife Sciences
AbCellera Biologics (ABCL) Q4 Revenue Surge Tests High 20.1x P/S Growth Narrative
AbCellera Biologics (NasdaqGS:ABCL) opened its Q1 2026 reporting season with recent quarterly revenue figures of US$44.9 million in Q4 2025 and a reported loss of US$8.9 million. This equates to basic EPS of US$0.03. On a trailing 12 month basis, revenue sits at US$75.1 million with EPS at US$0.49 and net income losses of US$146.4 million. Over the past year, the company has seen quarterly revenue move between US$4.2 million and US$44.9 million alongside quarterly EPS ranging from US$0.03 to...